Phathom Pharmaceuticals, Inc. Stock Price, News & Analysis

Phathom Pharmaceuticals (Nasdaq: PHAT) has completed patient enrollment in its pivotal Phase 3 clinical trial, PHALCON-HP, evaluating vonoprazan for H. pylori infection. The trial includes over 1,000 patients and aims to provide topline results in Q2 2021. The company also expects to submit a New Drug Application for H. pylori treatment in H2 2021. Vonoprazan, a potassium-competitive acid blocker, has shown promise in eradicating H. pylori and has received FDA Fast Track designation. The trial's success could significantly address rising antibiotic resistance.

Phathom Pharmaceuticals (Nasdaq: PHAT) announced a public offering of 2,250,000 shares at $42.00 per share, aiming for gross proceeds of $94.5 million before expenses. The offering is expected to close around December 21, 2020. Proceeds will fund clinical development of vonoprazan, a treatment for gastrointestinal diseases, and cover general corporate needs. Underwriters have a 30-day option to purchase an additional 337,500 shares. Jefferies, Evercore ISI, Guggenheim Securities, and BMO Capital Markets are managing the offering.

Phathom Pharmaceuticals (Nasdaq: PHAT) announced plans for a public offering of 2,250,000 shares of common stock, with an option for underwriters to purchase an additional 337,500 shares. The offering aims to fund the clinical development of vonoprazan, a treatment for gastrointestinal diseases. The net proceeds will also support working capital and pre-commercial activities. The offering is subject to market conditions, and a detailed prospectus will be filed with the SEC.

Phathom Pharmaceuticals (Nasdaq: PHAT) announced an expansion of its vonoprazan development program to include non-erosive reflux disease (NERD). This condition affects over 65 million U.S. patients with GERD, with two-thirds suffering from NERD. The program will assess dosage flexibility through clinical trials, with a Phase 2 trial expected to start in mid-2021. The company aims to address limitations in current treatments, utilizing feedback from the FDA. Phathom is simultaneously conducting pivotal trials for erosive esophagitis and H. pylori eradication.

Phathom Pharmaceuticals (Nasdaq: PHAT) announces the completion of patient enrollment in its pivotal Phase 3 clinical trial, PHALCON-EE, for vonoprazan, targeting the healing and maintenance of erosive esophagitis (EE) and heartburn relief. The trial exceeded its enrollment goal of 1,000 patients, with topline results expected in the second half of 2021. This trial complements another study, PHALCON-HP, assessing vonoprazan in H. pylori eradication. Vonoprazan has demonstrated promising efficacy and safety as a potassium-competitive acid blocker, recently receiving Fast Track designation from the FDA.

Phathom Pharmaceuticals (Nasdaq: PHAT) announced its management team will participate in two virtual investor conferences in December 2020:

• Evercore ISI 3rd Annual HealthCONx Conference
  Date: December 1, 2020
  Live Presentation Time: 10:55 am ET
• Piper Sandler 32nd Annual Virtual Healthcare Conference
  Date: December 2, 2020
  Pre-recorded presentation available online

Additionally, one-on-one meetings will be held during these events. For access to the presentations, visit Phathom's website.

Phathom Pharmaceuticals (Nasdaq: PHAT) will host a virtual Investor Day on December 14, 2020, from 1 PM to 3:30 PM ET. The event will feature members of Phathom's management team and gastroenterology experts discussing the company's pipeline and commercial strategy. Interested participants can pre-register for the event. A replay and presentation slides will be available post-event on Phathom's website.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced that its management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 3:15 p.m. GMT (10:15 a.m. ET). The conference runs from November 17-19, 2020, where the team will also engage in one-on-one meetings. Interested parties can access the live webcast and recorded presentations via the Phathom website. The company specializes in developing treatments for gastrointestinal diseases, focusing on the novel potassium competitive acid blocker, vonoprazan.

Phathom Pharmaceuticals (Nasdaq: PHAT) reported third-quarter 2020 financial results and provided updates on its pivotal Phase 3 clinical trials for vonoprazan. The company expects to complete enrollment in the PHALCON-EE trial by year-end 2020 and in the PHALCON-HP trial by Q1 2021. Top-line results are anticipated in mid-2021. The net loss for Q3 2020 was $34.1 million, down from $68.1 million in Q3 2019. Cash and equivalents stood at $226.4 million as of September 30, 2020. Phathom is enhancing its team with seasoned biopharmaceutical leaders in preparation for vonoprazan’s potential launch.